(R,S)-ketamine and (2R,6R)-hydroxynorketamine differentially affect memory as a function of dosing frequency

被引:13
|
作者
Riggs, Lace M. [1 ,2 ,3 ]
An, Xiaoxian [3 ]
Pereira, Edna F. R. [4 ,5 ]
Gould, Todd D. [3 ,5 ,6 ,7 ]
机构
[1] Univ Maryland, Program Neurosci, Sch Med, Baltimore, MD 21201 USA
[2] Univ Maryland, Training Program Integrat Membrane Biol, Sch Med, Baltimore, MD 21201 USA
[3] Univ Maryland, Dept Psychiat, Sch Med, Baltimore, MD 21201 USA
[4] Univ Maryland, Dept Epidemiol & Publ Hlth, Div Translat Toxicol, Sch Med, Baltimore, MD 21201 USA
[5] Univ Maryland, Dept Pharmacol, Sch Med, Baltimore, MD 21201 USA
[6] Univ Maryland, Dept Anat & Neurobiol, Sch Med, Baltimore, MD 21201 USA
[7] Vet Affairs Maryland Hlth Care Syst, Baltimore, MD 21201 USA
关键词
TREATMENT-RESISTANT DEPRESSION; INTRAVENOUS SUBANESTHETIC KETAMINE; NMDA RECEPTOR BLOCKADE; COGNITIVE IMPAIRMENT; OBJECT RECOGNITION; NEUROCOGNITIVE PERFORMANCE; PREFRONTAL CORTEX; NEGATIVE SYMPTOMS; INDUCED DEFICITS; DOUBLE-BLIND;
D O I
10.1038/s41398-021-01685-0
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
A single subanesthetic infusion of ketamine can rapidly alleviate symptoms of treatment-resistant major depression. Since repeated administration is required to sustain symptom remission, it is important to characterize the potential untoward effects of prolonged ketamine exposure. While studies suggest that ketamine can alter cognitive function, it is unclear to what extent these effects are modulated by the frequency or chronicity of treatment. To test this, male and female adolescent (postnatal day [PD] 35) and adult (PD 60) BALB/c mice were treated for four consecutive weeks, either daily or thrice-weekly, with (R,S)-ketamine (30 mg/kg, intraperitoneal) or its biologically active metabolite, (2R,6R)-hydroxynorketamine (HNK; 30 mg/kg, intraperitoneal). Following drug cessation, memory performance was assessed in three operationally distinct tasks: (1) novel object recognition to assess explicit memory, (2) Y-maze to assess working memory, and (3) passive avoidance to assess implicit memory. While drug exposure did not influence working memory performance, thrice-weekly ketamine and daily (2R,6R)-HNK led to explicit memory impairment in novel object recognition independent of sex or age of exposure. Daily (2R,6R)-HNK impaired implicit memory in the passive-avoidance task whereas thrice-weekly (2R,6R)-HNK tended to improve it. These differential effects on explicit and implicit memory possibly reflect the unique mechanisms by which ketamine and (2R,6R)-HNK alter the functional integrity of neural circuits that subserve these distinct cognitive domains, a topic of clinical and mechanistic relevance to their antidepressant actions. Our findings also provide additional support for the importance of dosing frequency in establishing the cognitive effects of repeated ketamine exposure.
引用
收藏
页数:12
相关论文
共 50 条
  • [21] Lack of Antidepressant Effects of (2R,6R)-Hydroxynorketamine in a Rat Learned Helplessness Model: Comparison with (R)-Ketamine
    Shirayama, Yukihiko
    Hashimoto, Kenji
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2018, 21 (01): : 84 - 88
  • [22] Effectiveness of Ketamine and (2R,6R)-Hydroxynorketamine to Reverse Anhedonia Subtypes Induced by Stress in Mice
    Georgiou, Polymnia
    Rajasekar, Thatchana
    Liu, Chao
    Zanos, Panos
    Gould, Todd
    NEUROPSYCHOPHARMACOLOGY, 2019, 44 (SUPPL 1) : 136 - 136
  • [23] Mediation of the behavioral effects of ketamine and (2R,6R)-hydroxynorketamine in mice by kappa opioid receptors
    Wulf, Hildegard A.
    Browne, Caroline A.
    Zarate, Carlos A.
    Lucki, Irwin
    PSYCHOPHARMACOLOGY, 2022, 239 (07) : 2309 - 2316
  • [24] Antidepressant-relevant concentrations of the ketamine metabolite (2R,6R)-hydroxynorketamine do not block NMDA receptor function
    Lumsden, Eric W.
    Troppoli, Timothy A.
    Myers, Scott J.
    Zanos, Panos
    Aracava, Yasco
    Kehr, Jan
    Lovett, Jacqueline
    Kim, Sukhan
    Wang, Fu-Hua
    Schmidt, Staffan
    Jenne, Carleigh E.
    Yuan, Peixiong
    Morris, Patrick J.
    Thomas, Craig J.
    Zarate, Carlos A., Jr.
    Moaddel, Ruin
    Traynelis, Stephen F.
    Pereira, Edna F. R.
    Thompson, Scott M.
    Albuquerque, Edson X.
    Gould, Todd D.
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2019, 116 (11) : 5160 - 5169
  • [25] Lack of Antidepressant Effects of (2R,6R)-Hydroxynorketamine in a rat Learned Helplessness Model: Comparison With (R)-Ketamine and (R)-Norketamine
    Shirayama, Yukihiko
    Hashimoto, Kenji
    NEUROPSYCHOPHARMACOLOGY, 2017, 42 : S542 - S543
  • [26] Common Neurotransmission Recruited in (R,S)-Ketamine and (2R, 6R)-Hydroxynorketamine-Induced Sustained Antidepressant-like Effects
    Thu Ha Pham
    Defaix, Celine
    Xu, Xiaoming
    Deng, Shi-Xian
    Fabresse, Nicolas
    Alvarez, Jean-Claude
    Landry, Donald W.
    Brachman, Rebecca A.
    Denny, Christine A.
    Gardier, Alain M.
    BIOLOGICAL PSYCHIATRY, 2018, 84 (01) : E3 - E6
  • [27] Ketamine metabolite (2R,6R)-hydroxynorketamine enhances aggression via periaqueductal gray glutamatergic transmission
    Ye, Lichao
    Ko, Chih-Yuan
    Huang, Yuting
    Zheng, Chen
    Zheng, Yanfang
    Chou, Dylan
    NEUROPHARMACOLOGY, 2019, 157
  • [28] Target Deconvolution Studies of (2R,6R)-Hydroxynorketamine: An Elusive Search
    Bonaventura, Jordi
    Gomez, Juan L.
    Lam, Sherry
    Soto, Marta Sanchez
    Morris, Patrick J.
    Zanos, Panos
    Moaddel, Ruin
    Gould, Todd D.
    Sibley, David R.
    Thomas, Craig J.
    Zarate, Carlos A., Jr.
    Michaelides, Mike
    NEUROPSYCHOPHARMACOLOGY, 2021, 46 (SUPPL 1) : 194 - 194
  • [29] Target deconvolution studies of (2R,6R)-hydroxynorketamine: an elusive search
    Jordi Bonaventura
    Juan L. Gomez
    Meghan L. Carlton
    Sherry Lam
    Marta Sanchez-Soto
    Patrick J. Morris
    Ruin Moaddel
    Hye Jin Kang
    Panos Zanos
    Todd D. Gould
    Craig J. Thomas
    David R. Sibley
    Carlos A. Zarate
    Michael Michaelides
    Molecular Psychiatry, 2022, 27 : 4144 - 4156
  • [30] Pharmacological evaluation of clinically relevant concentrations of (2R,6R)-hydroxynorketamine
    Shaffer, Christopher L.
    Dutra, Jason K.
    Tseng, Wei Chou
    Weber, Mark L.
    Bogart, Luke J.
    Hales, Katherine
    Pang, Jincheng
    Volfson, Dmitri
    Ende, Christopher W. Am
    Green, Michael E.
    Buhl, Derek L.
    NEUROPHARMACOLOGY, 2019, 153 : 73 - 81